Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib in recurrent glioblastoma
NCT01582269Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2012
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of galunisertib in glioblastoma (GBM), sponsored by Eli Lilly and Company. Started Apr 2012; status: completed.
02
Drugs
galunisertib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01582269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01582269.